Neoadjuvant nivolumab plus chemotherapy extends EFS in non-small cell lung cancer
Neoadjuvant nivolumab plus chemotherapy significantly improved EFS in stage IB to stage IIIA resectable non-small cell lung cancer, according to research presented at American Association for Cancer Research Annual Meeting. Results of the randomized phase 3 CheckMate 816 trial, published simultaneously in The New England Journal of Medicine, also showed no new adverse events associated with the